research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Sex Hormones and Related Compounds, Including Hormonal Contraceptives
The document concludes that sex hormones and related compounds have various effects on health, with both potential benefits and risks.
research Hormonal Regulation and Systemic Signals of Skin Aging
Hormones affect skin aging, and treatments targeting hormonal balance may improve skin health.
research Management of Breast Pain
The document concludes that breast pain should be managed with personalized treatment, starting with non-drug methods and progressing to medication if necessary, while considering side effects and patient needs.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Tamoxifen-Induced Total Alopecia
Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
research 61537 No Increased Risk of Breast or Gynecologic Cancers in Women with 5α-Reductase Inhibitor Exposure for Female Pattern Hair Loss: A Population-Based Propensity Score-Matched Cohort Study
Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
RU 58841 may treat acne, hair loss, and excessive hair growth.
research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
research The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
research Bicalutamide
research Alopecia in oncology: the practical significance of fundamental research
Chemotherapy often causes hair loss in cancer patients, affecting their mental health, but scalp cooling can help prevent it.
research Líquen plano pilar e alopecia frontal fibrosante: correlação dos achados clínicos e dermatoscópicos com o grau de inflamação do exame histopatológico
Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.
research Gender Differences in Production and Circulating Levels of Sex Hormones and Their Impact on Aging Skin
Men and women experience skin aging differently due to changes in sex hormone levels with age.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS ) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Synthesis and 5α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-diene or 4,6-diene 20-ones and 4-Azasteroid 20-Oximes
Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
research Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Androgen Therapy for Postmenopausal Women; What is New?
research Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
5-alpha reductase inhibitors do not increase hip fracture risk.
research Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles.
RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research Experimental Assessment of 3-<i>meta</i>-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors <i>in silico</i> and <i>in vivo</i> Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Finasteride/flibanserin
research Selective androgen receptor modulators: a critical appraisal
SARMs show promise but need more evidence to prove they're better than traditional androgens.